Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.55% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.85M USD | Price to earnings Ratio 0.21 | 1Y Target Price 7.5 |
Price to earnings Ratio 0.21 | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1 | Beta -0.52 | 52 Weeks Range 0.14 - 3.97 | Updated Date 08/28/2025 |
52 Weeks Range 0.14 - 3.97 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.85 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.74 | Actual -0.17 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -207.41% | Return on Equity (TTM) -612.3% |
Valuation
Trailing PE 0.21 | Forward PE - | Enterprise Value 4432869 | Price to Sales(TTM) - |
Enterprise Value 4432869 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 33466800 | Shares Floating 33361698 |
Shares Outstanding 33466800 | Shares Floating 33361698 | ||
Percent Insiders 0.33 | Percent Institutions 2.23 |
Upturn AI SWOT
Genprex Inc
Company Overview
History and Background
Genprex, Inc. is a clinical-stage gene therapy company founded in 2009. It focuses on developing therapies for cancer and diabetes based on its gene therapy platforms.
Core Business Areas
- Oncoprexu00ae Immunogene Therapy: Genprex's lead drug candidate, REQORSAu2122 (quaratusugene ozeplasmid), is being developed using the Oncoprex platform for non-small cell lung cancer (NSCLC).
- GPX-002: A preclinical-stage therapy for Type 1 and Type 2 diabetes.
- Research and Development: Focuses on advancing gene therapy technologies for various diseases.
Leadership and Structure
Genprex has a board of directors and an executive team led by the CEO. The organizational structure consists of departments focused on research, clinical development, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- REQORSAu2122 (quaratusugene ozeplasmid): A gene therapy targeting tumor suppressor genes. Currently in clinical trials for NSCLC. Market share is currently 0 as the product is not yet commercially available. Competitors include companies developing targeted therapies and immunotherapies for NSCLC, such as AstraZeneca (AZN), Merck (MRK), and Bristol-Myers Squibb (BMY).
- GPX-002: A gene therapy designed to reprogram pancreatic cells to treat Type 1 and Type 2 diabetes. Currently in preclinical development. Competitors include Novo Nordisk (NVO), Eli Lilly (LLY), and Sanofi (SNY).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in biotechnology and increasing investment in research and development. The market is characterized by high regulatory hurdles and significant clinical trial costs.
Positioning
Genprex is a small-cap company focused on gene therapy for cancer and diabetes. Its competitive advantage lies in its proprietary Oncoprex platform and its focus on underserved medical needs.
Total Addressable Market (TAM)
The global gene therapy market is expected to reach billions of dollars in the coming years. Genprex's TAM is tied to the NSCLC and diabetes markets. Given the specific subtypes of cancer and stages where REQORSA is being tested, Genprex's immediate TAM is smaller than the overall market but has significant growth potential. Specific numbers are difficult to predict due to clinical trial timelines and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary Oncoprex gene therapy platform
- Focus on unmet medical needs
- Clinical-stage drug candidate (REQORSAu2122)
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trial outcomes
- Competition from larger pharmaceutical companies
- Dependence on third-party manufacturing
Opportunities
- Positive clinical trial results for REQORSAu2122
- Partnerships with larger pharmaceutical companies
- Expansion of Oncoprex platform to other diseases
- Favorable regulatory environment for gene therapies
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from new and existing therapies
- Difficulty in securing funding
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
- NVO
- LLY
- SNY
Competitive Landscape
Genprex faces competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its unique gene therapy approach.
Growth Trajectory and Initiatives
Historical Growth: Genprex's historical growth is characterized by progression through preclinical and clinical development stages. Growth has been dependent on raising capital and achieving milestones in its clinical programs.
Future Projections: Future growth is contingent on the successful completion of clinical trials for REQORSAu2122 and GPX-002 and potential commercialization. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials for REQORSAu2122, securing financing, and exploring partnerships.
Summary
Genprex is a clinical-stage gene therapy company with a promising platform. Its success is heavily dependent on positive clinical trial outcomes for REQORSA and GPX-002. The company faces competition from larger, well-established players. Securing funding and navigating regulatory hurdles are key challenges. Genprex's focus on unmet needs in cancer and diabetes presents a significant opportunity if its therapies prove effective and safe.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Genprex Inc. Investor Relations
- SEC Filings
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and is subject to change. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.genprex.com |
Full time employees 15 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.